

Significant improvement of systemic lupus erythematosus manifestation in children after autologous dendritic cell transfer: a case report and review of literature

Jonny, Terawan Agus Putranto, Yenny Purnama, Roedi Djatmiko, Martina Lily Yana, Enda Cindylosa Sitepu and Raoulia Irfon

Ther Adv Vaccines Immunother

2023, Vol. 11: 1–9

DOI: 10.1177/
25151355231186005

© The Author(s), 2023.
Article reuse guidelines:
sagepub.com/journals-
permissions

Abstract: Dendritic cells (DC) are postulated to play a role in autoimmune diseases such as Systemic Lupus Erythematosus (SLE). We reported a 13-year-old female SLE patient who presents with chronic arthritis accompanied by persistent fever, dyspnea, sleep disturbance, headache, stomatitis, rash, and muscle weakness. The supporting examinations showed abnormal blood cell counts, positive antinuclear antibody profile, serositis, and neuropathy. Immunosuppressants failed to improve the condition. DC-based vaccine derived from autologous peripheral blood which was introduced with SARS-CoV-2 protein was given to this patient. There was a significant improvement in clinical and laboratory findings. Thus, DC immunotherapy appears to be a potential novel therapy for SLE that needs to be studied.

Keywords: autoimmune, cell therapy, dendritic cell, immunotherapy, systemic lupus erythematosus

Received: 1 December 2022; revised manuscript accepted: 12 June 2023.

Introduction

Systemic Lupus Erythematosus (SLE) is an autoimmune disease with diverse clinical manifestations. Therefore, the diagnosis of this disease is difficult to establish.¹ Currently, the primary treatment of SLE is by administration of immunosuppressant agents, but the administration of these drugs often causes side effects that cannot be tolerated.² SLE occurs due to self-antibodies caused by innate and adaptive immune system dysfunction.³ Dendritic cells (DC) play an essential role in the innate and adaptive immune system. Therefore, DC dysfunction becomes a factor in the development of the disease.⁴ Furthermore, DC plays a role in SLE and other autoimmune diseases.⁵ Therefore, DC therapy, including in SLE, needs to be researched.

In this article, we discuss the case of a girl who has diverse clinical manifestations and is diagnosed with SLE. The patient's condition did

not improve after being given various immunosuppressant therapies. However, after the administration of DC immunotherapy, there was a significant improvement in the clinical conditions.

Case presentation

A girl aged 13 years came with complaints of pain in all body joints, especially both pelvis and left shoulder, for 3.5 months. The pain worsened with movement. Initially, the pain was recurrent, but it got heavier and did not improve with non-steroid anti-inflammatory drug administration. There was no history of trauma.

For 2 months, patients complained of persistent fever, with the highest reported temperature being 39°C, accompanied by shortness of breath, sleep disturbances, headaches, and sores on the lips. Routine blood tests at the time

Correspondence to:

Jonny
Faculty of Medicine,
Jakarta Veterans National
Development University,
Jakarta, Indonesia

Cellcure Center, Gatot
Soebroto Central Army
Hospital, Jl. Abdul
Rahman Saleh Raya No. 24
RT10/RW5, Jakarta 10410,
Indonesia

jonny_army@yahoo.com

Terawan Agus Putranto
Roedi Djatmiko
Martina Lily Yana
Enda Cindylosa Sitepu
Raoulia Irfon
Cellcure Center, Gatot
Soebroto Central Army
Hospital, Jakarta,
Indonesia

Yenny Purnama
Pediatric Department
Gatot Soebroto Central
Army Hospital, Jakarta,
Indonesia

showed abnormalities in blood cell counts (Hemoglobin 10.9 g/dL, Platelets 131,000/ μ L, Leukocytes 2630/ μ L), decreased hematocrit (HCT 32.9%), relative increase of lymphocytes (Lymphocytes 40.7%), increased coagulation time (87 mm/h), and increased C-reactive protein (CRP) titers (227.50 mg/L). On X-ray thorax and CT-scan, there was right pleural effusion. The patient was suspected of having dengue fever, but the NS1 (Nonstructural protein-1) antigen rapid test result was negative. After 4 days, platelet counts were improved (233,000/ μ L), but the patient still had anemia, leukopenia, and increased CRP. Because there was no improvement, the patient was referred to a neurologist and psychiatrist. The head CT-scan showed no abnormalities.

Two weeks prior, the patient had persistent fever and led to hospitalization in *Pediatric Intensive Care Unit*. The complaints were accompanied by joint pain throughout the body, weakness, sometimes coughing and swallowing pain, and rashes on both forearms and lower limbs. The patient appears limp with hypotension (70/40 mmHg). Physical examination revealed that the patient appeared anemic. Bilateral subconjunctival bleeding, right neck lymphadenopathy, and petechiae on both forearms and lower legs were found [Figure 1(a) and (b)]. Motor functions were decreased in the lower limbs (right motor function scale: four out of five and left: three out of five), while the upper limbs were within normal limits. Laboratory examination showed pancytopenia (Hemoglobin 6.5 g/dL; Leukocytes 1420/ μ L, Platelets 54,000/ μ L), coagulation system disruption (elongated prothrombin time, fibrinogen and D-Dimer increased), increased SGPT (64 μ L), increased Lactate Dehydrogenase (361 μ L), hypoalbuminemia (3 g/dL), mild hyponatremia (132 mEq/L), increased procalcitonin (5.92 ng/mL), and increased CRP (316 mg/L). In blood cultures, *Staphylococcus aureus* were found.

Peripheral blood smears showed erythrocytes that were microcytic, hypochromic, anisopoikilocytosis and fragmented, with the presence of pencil cells and teardrop cells. Leukocytes appeared to have toxic granulation with atypical lymphocytes. In addition, giant thrombocytes were found.

There was a bilateral paracardial infiltration on the X-ray examination of the thorax [Figure 1(c)

and (d)]. Electromyography (EMG) examination suggested chronic denervation lesions with a picture of giant potential, in accordance with spinal muscular atrophy. Furthermore, examination of the nerve conduction velocity showed the presence of motor axonal neuropathy in the left ulnar and posterior tibial nerve. Antinuclear antibody (ANA) serological examination was conducted with a positive result of titer 1/100 with a rough speckled picture, positive anti-U1-Ribonucleoprotein, and positive anti-Smith. Anti-double strain Deoxyribose Nucleic Acid (dsDNA) and complement were within the normal limits.

The patient was given conservative treatment as well as intravenous antibiotics. During treatment, the patient experienced epistaxis that led to a transfusion-packed red cell and thrombocyte concentrate of 10 cc/kg. Methylprednisolone was also given intravenously at 50 mg/12h in two doses, followed by an Intravenous Immunoglobulin (IVIG) drip of 94,000 mg. After administering such therapy, the clinical condition was stable, but complaints of fever loss, joint pain, and weakness of the limbs remained. The patient went home against medical advice and did not take any drugs.

The patient came to our hospital 3 days post-hospitalization. We diagnosed SLE with a score of 24 based on the 2019 EULAR/ACR criteria. The findings included a positive ANA test, persistent fever, serositis (pleural effusion), leukopenia, thrombocytopenia, hemolysis anemia, joint pain, and neurological disorders. Meanwhile, based on the Systemic Lupus International Collaborating Clinics (SLICC) criteria, we found one immunological criterion and six clinical criteria that met the SLE diagnosis. The total of SELENA-SLEDAI score was 29.

Dendritic cells are obtained from incubation of autologous peripheral blood monocytes with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Interleukin-4 (IL-4). To obtain a maturing dendritic cell, incubation was carried out with the SARS-CoV-2 S-protein. DC was made under standard procedures, and as much as 0.5 cc (estimated 0.5–8 million autologous dendritic cells per dose) was subcutaneously injected into the left arm. One day after the vaccination, pain gradually improved. There was an improvement in motor function, evidenced by the patient's ability to walk with aids. One week after




Figure 1. (a) Stomatitis at the upper and lower lips. (b) Rash and petechiae in the upper extremity. (c) Thorax X-ray radiography before vaccination shows thickening of the right pleura (circle) indicating a pleural effusion. (d) Postvaccination thorax X-ray shows a normal condition.

the injection, the patient could move independently and walk without any aids. Clinical improvement was also supported by laboratory findings, where routine blood examination and peripheral blood smear test were within the normal limits.

At 1-month post-injection evaluation, the patient had no complaints. Motor examination of upper and lower limbs was within the normal limits (left and right motor function: five out of five). Laboratory examination and X-ray of the thorax were within the normal limits. There was a significant change in the SELENA-SLEDAI score with a total of 0. The patient had a mild relapse (swelling and pain of the joints) after 3-month post-injection and was treated with Ibuprofen 200mg two times daily.

Discussion

In this case, an SLE is obtained in a 13-year-old child. The manifestations of SLE are very diverse,

so it is a complicated diagnosis.⁶ Nevertheless, clinical manifestations in the patient support the diagnosis of SLE, that is, ANA positive test accompanied by persistent fever, serositis (pleural effusion), stomatitis, leukopenia, thrombocytopenia, hemolysis anemia, arthritis, and neurological disorders.

The challenge in developing dendritic cell transfer for therapy of SLE is that to make sure that these cells will not revert to the immunogenic state under inflammatory conditions, thus exacerbating the symptoms.⁷ On the contrary, we found that significant clinical improvement occurred immediately after the autologous DC was being administered. Physical, laboratory, and radiology examinations were obtained normally after 1-month postvaccination. Patients did not receive any therapy for SLE 10 days before and still did not get any therapy after vaccination. This proves the safety of autologous DC transfer in children with SLE. In addition, significant improvement of symptoms shows that there is a therapeutic potential in this approach.

Dendritic cells (DC) are the most potential Antigen Presenting Cells in the immune system that also act as immune tolerance.⁸ The outcome of DC interactions with T cells is determined by maturation, subset type, microenvironment, and location. Although the conditions that cause DC to have tolerogenic functions are well known, the process of tolerance induction by this DC is still unclear.^{8,9,10} In general, DC can control the tolerance through the formation of regulatory T (Treg) cells by the surface molecules (Cluster of Differentiation (CD) 70, CD80/86, Inducible costimulator-ligand (ICOS-L), Programmed Death Ligand-1 (PD-L1), and Programmed Death Ligand-2 (PDL1)) and secretion of tolerance-inducing factors (TGF β , IL-10, and IL-27).⁸ One method that is proposed to induce tolerogenic DC is by using an immature DC (not yet exposed to antigens) that will interact with T cells suboptimally causing anergy.¹¹ However, there is evidence that mature DC is more efficient at inducing tolerance through the differentiation of Treg cells.¹⁰ This process is also possible to control autoimmune states [Figure 2(a)].

Inducing tolerogenic DC can be done in a variety of ways. Recent developments suggest that the addition of part of the pathogen may also elicit a tolerance response. DC isolated from mice spleen showed suppressive phenotypes after being introduced with lipopolysaccharide (LPS) or lipoteichoic acid (LTA).¹² Other studies have shown that semi-mature DC of SLE patients incubated with a combination of vitamin D3 and dexamethasone, then matured with LPS, elicits a better tolerogenic response compared to immature DC.¹³ Recently, there is also strong evidence showing that mature DC can induce tolerogenic response by inducing Foxp3+ T reg.⁷ *In vitro* DC culture with probiotic bacteria (*Lactobacillus salivarius*, *Bifidobacterium bifidum*, *Bacillus coagulans*, and *Bacillus subtilis*) can also give rise to tolerogenic DC.¹⁴ Tolerogenic DC can also be obtained through differentiation of monocyte-derived dendritic cells with cytokines IL-10 and TGF- β , inhibiting *in vitro* differentiation of DC with immunosuppressive agents (glucocorticoids, vitamin D3, mofetil mycophenolate, and rapamycin), and manipulation of immunosuppressive genetic elements in DC [cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), indoleamine 2,3-dioxygenase 1 (IDO), Fas Ligand (FasL), and

tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)].¹¹

In this case, DC was introduced to the SARS-CoV-2 S-protein. This approach was initially developed as a vaccine to prevent COVID-19. The previous study has shown that *ex vivo* DC incubation with peptides from the S-protein SARS-CoV-2 can elicit an immunogenic response in the body through the response of T cells and B cells.^{15,16} However, this case suggests the possibility that the DC vaccine can also control autoimmune through the tolerogenic response of the DC. Several things that need to be considered in future research are the possibility of special conditions or factors that can cause a tolerogenic response from DC introduced to the SARS-CoV-2 S-protein, such as autoimmune conditions triggered after SARS-CoV-2 infection, genetic variations of DC obtained from people with autoimmune diseases, or the use of immunosuppressive agents such as vitamin D3 and glucocorticoid.

Immunopathologically, SLE occurs due to impaired tolerance of the central and peripheral immune system where there are abnormalities in the elimination of body cells undergoing apoptosis and necrosis.¹⁷ This can lead to the self-release of DNA/RNA which will stimulate plasmacytoid DC (pDC) resulting in the production of interferon type I (IFN-I).³ This increase in IFN-I production leads to DC differentiation so that there will be an increase in pro-inflammatory cytokines. DC will present *self*-antigens so that autoreactive lymphocytes are formed.⁴ In SLE patients, there is an increase in the number and activity of Th-17 cells, and a decrease in Treg that will lead to autoimmunity. In addition, there is Th-1 cell dysfunction and Th-2 cell hyperfunction that will cause activation of various types of B cells that produce autoantibodies.¹⁸ The immune complexes of antigens and autoantibodies formed cause damage to various tissues.¹⁹ This process of disruption of the natural and innate immune system takes place continuously and forms the chain of the pathogenesis of SLE [Figure 2(b)].

DC immunotherapy in autoimmune patients has been studied before. Preclinical trials of tolerogenic DC administration in mice with rheumatoid




Figure 2. (a) Postulated dendritic cell role in controlling autoimmunity in SLE. Tol-DC presents antigen to naïve DC which causes differentiation of naïve T cell to Treg cell. Otherwise, immature DC differentiates naïve T cells which leads to T cell anergy. These conditions control the autoimmunity and activation of anti-inflammation states in SLE. (b) The immunopathogenesis of SLE. Apoptotic or necrotic cells release their self-DNA/RNA which is captured by DC. This process induced increasing antigen presentation to B and T cells and leads to their differentiation into autoreactive cells. B cell will secrete autoantibodies otherwise Th-17 will be produced with a decrease in T regulatory count. This condition leads to autoimmunity and hyper inflammation state in SLE.

arthritis showed that tolerogenic DC may decrease CD4⁺ activation, decrease pro-inflammatory cytokines (IL-6), and increase anti-inflammatory cytokines (IL-10), and may improve clinical manifestation.²⁰ In another similar study, the administration of autologous tolerogenic DC derived from the bone marrow of mice suffering from SLE showed clinical improvement. This is characterized by a decrease in IL-6, IL-12, the number of anti-DNA antibodies, and anti-histone IgG, as well as an increase in the number of Treg cells.

However, the administration of tolerogenic DC was not accompanied by improvements in proteinuria and glomerulonephritis.²¹

To date, several clinical trials of DC immunotherapy have been conducted for autoimmune diseases.²² Administration of DC introduced with autologous synovial fluid intra-articularly in subjects with rheumatoid arthritis showed good safety, tolerability, and efficacy. This is indicated by the absence of flares during the observation

Table 1. Supporting examination finding before and after vaccination.

Parameter	Before vaccination		After vaccination	
	Results	Reference value	Results	Reference value
Hemoglobin(g/dL)	6.5	12–15	13.2	12–16
Hematocrit (%)	19.6	36–46	39	35–46
Erythrocyte (million/ μ L)	2.38	3.8–4.8	4.6	4.1–5.1
Mean corpuscular volume (fL)	82.4	83–101	86	78–102
Mean corpuscular hemoglobin (pg)	27.3	27–32	29	25–35
Mean corpuscular hemoglobin concentration (g/dL)	33.2	31.5–34.5	34	31–37
Platelets (/ μ L)	54	150,000–400,000	310,000	150,000–400,000
Leucocyte (μ L)	1420	4000–10,000	6370	4500–13,500
Basophile (%)	0.7	0–2	1	0–1
Eosinophile (%)	0	1–6	4	1–3
Neutrophil (%)	60.6	40–80	42	50–70
Lymphocyte (%)	31.7	20–40	47	20–40
Red blood cell distribution width (%)	14.9	11.6–14.0	14.5	11.5–14.5
ANA Test	1:100	negative	<1/80	<1/80
Anti-U1-Ribonucleoprotein	positive	negative	negative	negative
Anti-Smith	positive	negative	negative	negative
Anti-double strain-DNA	negative	negative	negative	negative
Serum glutamic-oxaloacetic transaminase (U/L)	30	<40	19	<35
Serum glutamic-pyruvic transaminase (U/L)	64	5.9–3.7	9	<40
Creatinine (mg/dL)	0.6	0.45–0.81	0.54	0.5–1.5
Ureum (mg/dL)	34.2	18–45	19	20–50
Lactate dehydrogenase (U/L)	361	125–220	175	<480
Procalcitonin (μ g/L)	5.92	<0.05	0.04	0.02–0.5
Quantitative C-reactive protein (mg/dL)	316	<5	0.1	<1
D-dimer (ng/mL)	9600	<440	480	<500
Peripheral blood smear				
Erythrocyte	Microcytic, hypochromic, anisopoikilocytosis, fragmentocytes +, pencil cells+, and teardrop cells +		Normochromic, normocytes, and equal cell distribution	

(Continued)

Table 1. (Continued)

Parameter	Before vaccination		After vaccination	
	Results	Reference value	Results	Reference value
Leukocyte	Low count with atypical lymphocytes, toxic granule, and left shifting		Normal count, normal morphology, and distribution	
Thrombocyte	Giant thrombocytes + and low count		Normal count and no giant thrombocytes	
Thorax radiology	Right pleural effusion		Normal	
Electromyography	Chronic denervation with a giant potential appearance suggestive of spinal muscular atrophy		Normal	
Nerve conduction velocity	Motoric axonal neuropathy of left ulnar and tibialis posterior nerves		Normal	
The bold values are abnormal findings (out of reference value).				

period and no increase in the severity of the disease.²³ Phase I clinical trials with type I Diabetes Mellitus (DM) subjects showed that DC immunotherapy was tolerable and there were no serious adverse events. However, the results of the study did not show any clinical changes in the subjects given the therapy.²⁴ Other research on the subject of type 1 DM is still ongoing and cannot be concluded.²⁵ Phase I clinical trials of DC immunotherapy in Multiple Sclerosis showed that patients given DC did not experience worsening during the follow-up phase. In addition, an increase in IL-10 was found to be associated with an increase in the number of Treg cells.²⁶ However, no results of clinical trials of DC immunotherapy on SLE have been published. From the results of the clinical trial, it can be seen that DC immunotherapies are potentially effective for autoimmune patients and have good safety. However, the efficacy of the use of this therapy in SLE still requires further research.

Conclusion

Herein, we report the first case of a patient with SLE showing significant clinical improvement after administration of the DC vaccine. It can be seen that DC immunotherapies are potentially effective in treating autoimmune diseases and have good safety. However, the efficacy of this approach to treat SLE still requires further research.

Declaration

Ethics approval and consent to participate

Written informed consent from the patient's parents and assent from the patient was obtained.

Consent for publication

Written informed consent for publication from the patient's parents and assent from the patient was obtained.

Author contributions

Jonny: Conceptualization; Data curation; Formal analysis; Resources; Supervision; Writing – original draft; Writing – review & editing.

Terawan Agus Putranto: Conceptualization; Formal analysis; Funding acquisition; Methodology; Resources; Supervision; Writing – review & editing.

Yenny Purnama: Conceptualization; Resources; Supervision; Writing – review & editing.

Roedi Djatmiko: Conceptualization; Resources; Supervision; Writing – review & editing.

Martina Lily Yana: Conceptualization; Data curation; Formal analysis; Investigation; Supervision; Validation; Writing – review & editing.

Enda Cindylosa Sitepu: Project administration; Resources; Visualization; Writing – original draft; Writing – review & editing.

Raoulian Irfon: Project administration; Resources; Visualization; Writing – original draft; Writing – review & editing.

Acknowledgements

None.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Competing interests

The authors declare that there is no conflict of interest.

Availability of data and materials

Data available on request due to privacy/ethical restrictions.

ORCID iD

Raoulian Irfon  <https://orcid.org/0000-0002-8180-4793>

References

1. Serra-García L, Barba PJ and Morgado-Carrasco D. RF-2019 Classification criteria for systemic lupus erythematosus. *Actas Dermosifiliogr* 2021; 71: 1400–1412.
2. Trindade VC, Carneiro-Sampaio M, Bonfa E, *et al.* An update on the management of childhood-onset systemic lupus erythematosus. *Pediatr Drugs* 2021; 23: 331–347.
3. Pan L, Lu MP, Wang JH, *et al.* Immunological pathogenesis and treatment of systemic lupus erythematosus. *World J Pediatr* 2020; 16: 19–30.
4. Kaewraemruan C, Ritprajak P and Hirankarn N. Dendritic cells as key players in systemic lupus erythematosus. *Asian Pacific J Allergy Immunol* 2020; 38: 225–232.
5. Ye Y, Gaugler B, Mohty M, *et al.* Plasmacytoid dendritic cell biology and its role in immune-mediated diseases. *Clin Transl Immunol* 2020; 9: 1–19.
6. Aringer M, Costenbader K, Daikh D, *et al.* 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol (Hoboken, Nj)* 2019; 71: 1400–1412.
7. Horwitz DA, Fahmy TM, Piccirillo CA, *et al.* Rebalancing immune homeostasis to treat autoimmune diseases. *Trends Immunol* 2019; 40: 888–908.
8. Waisman A, Lukas D, Clausen BE, *et al.* Dendritic cells as gatekeepers of tolerance. *Semin Immunopathol* 2017; 39: 153–163.
9. Macri C, Pang ES, Patton T, *et al.* Dendritic cell subsets. *Semin Cell Dev Biol* 2018; 84: 11–21.
10. Morel PA and Feili-Hariri M. How do dendritic cells prevent autoimmunity? *Trends Immunol* 2001; 22: 546–547.
11. Funes SC, Manrique de Lara A, Altamirano-Lagos MJ, *et al.* Immune checkpoints and the regulation of tolerogenicity in dendritic cells: implications for autoimmunity and immunotherapy. *Autoimmun Rev* 2019; 18: 359–368.
12. Yoon HS, Kim G, Ju YJ, *et al.* Distinct pattern of immune tolerance in dendritic cells treated with lipopolysaccharide or lipoteichoic acid. *Mol Immunol* 2017; 91: 57–64.
13. Wu HJ, Lo Y, Luk D, *et al.* Alternatively activated dendritic cells derived from systemic lupus erythematosus patients have tolerogenic phenotype and function. *Clin Immunol* 2015; 156: 43–57.
14. Ghavami SB, Yadegar A, Aghdaei HA, *et al.* Immunomodulation and generation of tolerogenic dendritic cells by probiotic bacteria in patients with inflammatory bowel disease. *Int J Mol Sci* 2020; 21: 1–15.
15. Nistor GI, Dillman RO, Robles RM, *et al.* A personal COVID-19 dendritic cell vaccine made at point-of-care: feasibility, safety, and antigen-specific cellular immune responses. *Hum Vaccines Immunother* 2022; 18: 2100189.
16. Jonny J, Putranto TA, Sitepu EC, *et al.* Dendritic cell vaccine as a potential strategy to end the COVID-19 pandemic. Why should it be ex vivo? *Expert Rev Vaccines*. 2022; 21: 1111–1120.
17. Arneth B. Systemic lupus erythematosus and DNA degradation and elimination defects. *Front Immunol* 2019; 10: 1697.
18. Chen PM and Tsokos GC. T Cell abnormalities in the pathogenesis of systemic lupus erythematosus: an update. *Curr Rheumatol Rep* 2021; 23: 12.
19. Lo MS and Tsokos GC. Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. *Curr Opin Rheumatol* 2018;30:222–228.

20. Jansen MAA, Spiering R, Ludwig IS, *et al.* Matured tolerogenic dendritic cells effectively inhibit autoantigen specific CD4⁺ T cells in a murine arthritis model. *Front Immunol* 2019; 10: 1–12.
21. Funes SC, Rios M, Gómez-Santander F, *et al.* Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice. *Immunology* 2019; 158: 322–339.
22. Ness S, Lin S and Gordon JR. Regulatory dendritic cells, T cell tolerance, and dendritic cell therapy for immunologic disease. *Front Immunol* 2021;12.
23. Bell GM, Anderson AE, Diboll J, *et al.* Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. *Ann Rheum Dis* 2017; 76: 227–234.
24. Giannoukakis N, Phillips B, Finegold D, *et al.* Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. *Diabetes Care* 2011; 34: 2026–2032.
25. Khan FU, Khongorzul P, Raki AA, *et al.* Dendritic cells and their immunotherapeutic potential for treating type 1 diabetes. *Int J Mol Sci* 2022; 4.
26. Zubizarreta I, Flórez-Grau G, Vila G, *et al.* Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. *Proc Natl Acad Sci USA* 2019; 116: 8463–8470.

Visit Sage journals online
[journals.sagepub.com/
 home/tav](https://journals.sagepub.com/home/tav)

 Sage journals